CAMBRIDGE, MASSACHUSETTS, MARCH 12, 2021 – Paragonix Technologies, Inc. announced today that Lisa Anderson, Ph.D., has been elevated to the role of CEO.
Dr. Anderson succeeds William Edelman, who has served as Chairman and CEO since 2012 and recently announced his retirement. John Cammett, member of the Board for over three years, will assume the role of Chairman of the Board of Directors.
Dr. Anderson brings a wealth of experience to this role, having founded Paragonix and served as the company’s Chief Operating Officer for the past 10 years. Lisa has played a critical role in the company’s continued growth, including commercially scaling the business across the United States and Europe, overseeing the launch of critically-acclaimed products, Paragonix SherpaPak® Cardiac Transport System and the LUNGguard™ Donor Lung Preservation System, and the recent rollout of a first-of-its-kind digital platform for transplant team coordination and clinical logistics.
Mr. Cammett commented, “The depth and breadth of Dr. Anderson’s unique experience at Paragonix both from a clinical and well as multinational commercial development perspective underpins her natural progression into the role of CEO.” Mr. Cammett continued, “There is no better person to take over the helm of Paragonix than Lisa. Under Lisa’s leadership, the company will be establishing a new era of broad market adoption and expansion of technologies underpinning the product portfolio. Her leadership in the field of organ preservation and deep connection to the transplant community makes her the perfect leader for this new chapter in the company’s growth”.
Dr. Anderson commented, “I am thrilled to lead a highly distinguished team that is on track to bring Paragonix to the next level by expanding our product profile and digitally integrating our full suite to empower both donation and transplant professionals. Our goal is to provide every transplant patient the advantage of advanced organ preservation through collaboration with all the varied stakeholders in the transplant community.” This next era for Paragonix is built upon the foundation Edelman cultivated: “Under Bill’s leadership, Paragonix defined the pathway to a new method of care, achieved multiple FDA clearances and CE marks, and launched two groundbreaking commercial products. We thank him for eleven years of dedicated service.”
As part of his retirement remarks, Mr. Edelman underscored his pride in the milestones Paragonix has reached throughout his tenure, “Our products are on a clear path to becoming standard of care. What’s more, I look forward to seeing Paragonix continue to evolve and strengthen under Dr. Anderson’s leadership and unwavering commitment to the transplant community.”
About Paragonix Technologies
Paragonix Technologies designs, produces, and markets organ preservation and transport devices that safeguard organs during the journey between donor and transplant recipient patients. Our award-winning devices mitigate risk in an otherwise high stakes environment by combining best-in class transplant products with a centralized communication and data transfer app to enable better coordination and efficiency during donor organ procurements. Paragonix SherpaPak® CTS is the only commercially available FDA-cleared and CE-marked preservation and transport device for adult and pediatric donor hearts destined for transplantation. Paragonix is the sole sponsor of GUARDIAN, the largest international clinical data registry on heart preservation, capturing clinical outcome data on Paragonix SherpaPak® CTS and all other heart preservation technologies. Paragonix’s LUNGguard™ is the only FDA-cleared and CE-marked cold storage preservation and transport device for donor lungs and was commercially launched in the US and in Europe in December 2020. Paragonix is also developing preservation devices for pancreas, kidney and liver — designed to improve donor organ quality and extend donor organ preservation time.